Приказ основних података о документу

dc.creatorAntić, Darko
dc.creatorMihaljević, Biljana
dc.creatorČokić, Vladan
dc.creatorDencic-Fekete, Marija
dc.creatorKaran-Đurašević, Teodora
dc.creatorPavlović, Sonja
dc.creatorMilić, Nataša
dc.creatorElezović, Ivo
dc.date.accessioned2021-04-20T12:23:56Z
dc.date.available2021-04-20T12:23:56Z
dc.date.issued2011
dc.identifier.issn1042-8194
dc.identifier.urihttp://rimi.imi.bg.ac.rs/handle/123456789/336
dc.description.abstractWe investigated molecular and biological parameters reflecting the biology of chronic lymphocytic leukemia (CLL) that may help us to predict the time to first treatment (TTT). A group of 33 patients with newly diagnosed CLL (Binet stage A) were analyzed. We developed a new scoring system based on the serum levels of beta(2)-microglobulin (beta M-2) and vascular endothelial growth factor (VEGF) and the expression of lipoprotein lipase (LPL). Patients with a score of 0 had a TTT of 58.4 months, while patients with a score of 3 (increased levels of beta M-2, LPL, and VEGF) had a significantly shorter TTT of only 10.6 months (p lt 0.0001).en
dc.publisherTaylor & Francis Ltd, Abingdon
dc.rightsrestrictedAccess
dc.sourceLeukemia & Lymphoma
dc.subjectLymphoma and Hodgkin diseaseen
dc.subjectmolecular geneticsen
dc.subjectprognosticationen
dc.titlePatients with early stage chronic lymphocytic leukemia: new risk stratification based on molecular profilingen
dc.typearticle
dc.rights.licenseARR
dc.citation.epage1397
dc.citation.issue7
dc.citation.other52(7): 1394-1397
dc.citation.rankM22
dc.citation.spage1394
dc.citation.volume52
dc.identifier.doi10.3109/10428194.2011.578311
dc.identifier.pmid21699385
dc.identifier.scopus2-s2.0-79959613190
dc.identifier.wos000291992400036
dc.type.versionpublishedVersion


Документи

Thumbnail

Овај документ се појављује у следећим колекцијама

Приказ основних података о документу